3-FA

Coronary artery disease, Cardiomyopathy, Cardiac arrhythmias, Structural heart defects, Heart failure

3-FA is a potent norepinephrine and dopamine releasing agent (NE EC₅₀ 16.1 nM, DA EC₅₀ 24.2 nM). The resulting peripheral sympathomimetic activation produces tachycardia, hypertension, and increased myocardial oxygen demand. In individuals with pre-existing cardiovascular disease, these effects can precipitate acute coronary syndrome, decompensated heart failure, or fatal arrhythmia. No substance-specific cardiovascular adverse event data exist for 3-FA; this contraindication is inferred from amphetamine class pharmacology and the confirmed NE-releasing mechanism.

Uncontrolled hypertension

3-FA releases norepinephrine and dopamine, producing acute blood pressure elevation. In individuals with uncontrolled hypertension, superimposed catecholamine-driven vasoconstriction and cardiac stimulation significantly increase the risk of hemorrhagic stroke, aortic dissection, and hypertensive emergency. No substance-specific data exist; contraindication is class-inferred from amphetamine pharmacology.

Epilepsy, Other seizure disorders

Amphetamine-type stimulants lower the seizure threshold through excessive catecholaminergic CNS stimulation. Individuals with epilepsy or other seizure disorders face elevated risk of breakthrough seizures. No substance-specific seizure data exist for 3-FA; this is a class-level contraindication inferred from amphetamine pharmacology.

Schizophrenia spectrum disorders, Schizoaffective disorder, History of stimulant-induced psychosis

3-FA's potent dopamine release (DA EC₅₀ 24.2 nM, producing 5–14-fold NAc DA elevation in rats) can precipitate or exacerbate psychotic episodes in individuals with schizophrenia spectrum disorders, schizoaffective disorder, or a history of stimulant-induced psychosis. Amphetamine-induced psychosis is a well-established syndrome characterized by paranoid delusions, auditory hallucinations, and disorganized thinking. Risk increases with dose, duration of use, and sleep deprivation.

Hyperthyroidism, Thyrotoxicosis

Hyperthyroidism increases the density and sensitivity of adrenergic receptors, amplifying the cardiovascular and thermoregulatory effects of catecholamine-releasing agents. 3-FA's potent NE release would produce exaggerated tachycardia, hypertension, and hyperthermia risk in hyperthyroid individuals. No substance-specific data exist; contraindication is class-inferred from amphetamine pharmacology.

Pregnancy

3-FA's catecholamine-releasing mechanism is expected to produce uterine vasoconstriction (reducing placental blood flow) and fetal tachycardia. No reproductive toxicity data exist for 3-FA in any species. The contraindication is absolute by class inference from amphetamine, where fetal harm from sympathomimetic exposure is well-documented.

Irreversible MAOI use, Reversible MAO-A inhibitor use, High-dose selegiline use

Combination of 3-FA with any monoamine oxidase inhibitor — including irreversible MAOIs (phenelzine, tranylcypromine), reversible MAO-A inhibitors (moclobemide), and selegiline at higher doses — is potentially lethal. The mechanism is well-established for the amphetamine class: MAO inhibition prevents intraneuronal degradation of released monoamines, resulting in massive synaptic accumulation of dopamine, norepinephrine, and serotonin. This produces hypertensive crisis and hyperthermia.